Marina Chiara Garassino to Neoplasms
This is a "connection" page, showing publications Marina Chiara Garassino has written about Neoplasms.
Connection Strength
2.701
-
The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate. Ann Oncol. 2021 05; 32(5):579-581.
Score: 0.271
-
At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer. Cancer Immunol Res. 2021 03; 9(3):261-264.
Score: 0.269
-
COVID-19 in patients with cancer: managing a pandemic within a pandemic. Nat Rev Clin Oncol. 2021 01; 18(1):1-2.
Score: 0.269
-
Caring for Patients With Cancer During the COVID-19 Outbreak in Italy. JAMA Oncol. 2020 06 01; 6(6):821-822.
Score: 0.258
-
Membrane Cholesterol Regulates Macrophage Plasticity in Cancer. Cell Metab. 2019 06 04; 29(6):1238-1240.
Score: 0.241
-
Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. Cancer Res. 2018 10 15; 78(20):5729-5730.
Score: 0.230
-
Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. PLoS One. 2013; 8(4):e59981.
Score: 0.157
-
Predictive models in palliative care. Cancer. 2009 Jul 01; 115(13 Suppl):3128-34.
Score: 0.121
-
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. Eur J Cancer. 2022 Dec; 177:175-185.
Score: 0.076
-
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations. JCO Glob Oncol. 2022 08; 8:e2200123.
Score: 0.075
-
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors. Eur J Intern Med. 2022 09; 103:95-99.
Score: 0.075
-
COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response. JAMA Oncol. 2021 12 01; 7(12):1882-1890.
Score: 0.072
-
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med. 2021 11; 93:87-94.
Score: 0.070
-
OncoAlert Round Table Discussions: The Global COVID-19 Experience. JCO Glob Oncol. 2021 04; 7:455-463.
Score: 0.068
-
Regulation of PD-L1 Expression by NF-?B in Cancer. Front Immunol. 2020; 11:584626.
Score: 0.067
-
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020 10; 31(10):1320-1335.
Score: 0.065
-
Immunometabolic Status of COVID-19 Cancer Patients. Physiol Rev. 2020 10 01; 100(4):1839-1850.
Score: 0.065
-
The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. Tumori. 2018 Mar-Apr; 104(2):88-95.
Score: 0.055
-
Cognitive impairment and chemotherapy: a brief overview. Crit Rev Oncol Hematol. 2017 Oct; 118:7-14.
Score: 0.053
-
Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. Virchows Arch. 2016 Apr; 468(4):451-61.
Score: 0.048
-
A mono-institutional prospective study on the effectiveness of a specialist psychotherapeutic intervention (POI) started at the diagnosis of cancer. Support Care Cancer. 2012 Mar; 20(3):475-81.
Score: 0.034
-
Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT). Anticancer Res. 2008 May-Jun; 28(3B):1767-71.
Score: 0.028
-
New anti-emetic treatments. Ann Oncol. 2007 Jul; 18 Suppl 9:ix43-7.
Score: 0.026
-
Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. Anticancer Drugs. 2013 Feb; 24(2):99-111.
Score: 0.010